<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Circulating miRNAs as potential non-invasive biomarkers for ANCA-associated glomerulonephritis</dc:title><dc:creator>Bošnjak,	Matic	(Avtor)
	</dc:creator><dc:creator>Večerić-Haler,	Željka	(Avtor)
	</dc:creator><dc:creator>Pipan Tkalec,	Živa	(Avtor)
	</dc:creator><dc:creator>Tomšič,	Jakob	(Avtor)
	</dc:creator><dc:creator>Boštjančič,	Emanuela	(Avtor)
	</dc:creator><dc:creator>Kojc,	Nika	(Avtor)
	</dc:creator><dc:subject>ANCA</dc:subject><dc:subject>biomarker</dc:subject><dc:subject>glomerulonephritis</dc:subject><dc:subject>microRNA</dc:subject><dc:subject>vasculitis</dc:subject><dc:subject>epigenetics</dc:subject><dc:description>Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by necrotizing small vessel vasculitis that frequently manifests as glomerulonephritis (AAV-GN). An accurate noninvasive biomarker reflecting active AAV-GN remains elusive. The knowledge of microRNAs (miRNAs), which have been considered as disease-specific biomarkers, is scarce and lacks validated data in AAV. Methods: This study validated a renal tissue expression profile of candidate miRNAs specific to AAV-GN selected through prior screening using independent cohorts. The analysis was extended to serum samples to explore the potential of a circulating miRNA panel as a noninvasive biomarker for active AAV-GN. To substantiate the findings, we correlated the molecular data with clinical and histologic markers of AAV-GN activity. Results: We identified miR-21-3p, miR-181a-5p, and miR-181d-5p as potential biomarkers distinguishing AAV-GN from non-AAV renal diseases and healthy controls. In addition, miR-21-3p and miR-181d-5p correlated with the presence of active AAV-GN, while miR-181a-5p differentiated AAV-GN subtypes based on ANCA antigen specificity. ROC curve analysis demonstrated that the combined serum expression of miR-21-3p and miR-181a-5p reliably distinguished AAV-GN from other renal pathologies, including ANCA-positive cases without histologic evidence of AAV-GN. Conclusion: Our findings highlight the potential of circulating miRNA expression signature as a noninvasive biomarker for ongoing AAV-GN in the appropriate setting. Larger confirmatory studies are essential to support the clinical application of miRNA-based biomarkers in AAV-GN diagnostics and disease monitoring.</dc:description><dc:date>2025</dc:date><dc:date>2025-11-26 13:53:17</dc:date><dc:type>Neznano</dc:type><dc:identifier>24387</dc:identifier><dc:identifier>UDK: 616-097</dc:identifier><dc:identifier>ISSN pri članku: 1664-3224</dc:identifier><dc:identifier>DOI: 10.3389/fimmu.2025.1599043</dc:identifier><dc:identifier>COBISS_ID: 246506499</dc:identifier><dc:language>sl</dc:language></metadata>
